Anebulo Pharmaceuticals Inc

NASDAQ:ANEB   1:29:46 PM EDT
2.39
-0.08 (-3.24%)
Products, Regulatory

Anebulo Pharmaceuticals Announces Positive Interim Data For Aneb-001 From Part B Of Its Phase 2 Clinical Trial For Acute Cannabinoid Intoxication

Published: 09/26/2022 11:10 GMT
Anebulo Pharmaceuticals Inc (ANEB) - Anebulo Pharmaceuticals Announces Positive Interim Data for Aneb-001 From Part B of Its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication.
Anebulo Pharmaceuticals Inc - Lower Doses of Aneb-001 Reduced Negative Effects of Higher Doses of Thc.
Anebulo Pharmaceuticals Inc - Currently Exploring Delayed Dosing Tobetter Understand Real-world Conditions.